Tranylcypromine

Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)

Retrieved on: 
星期四, 十二月 7, 2023
Health, Neurology, General Health, Research, Pharmaceutical, Science, COMT, Medicine, Capsule, Sleep, Aggression, BIAL, Brain, Behavior, NYSE, Hormone, Senior, Food, Parkinson's disease, Eating, Movement, Gambling, Liver, PD, Delusion, Hallucination, Constipation, Sleep disorder, Patient, Multimedia, Dopamine, Dobutamine, Carbidopa, Behavior informatics, FDA, Isocarboxazid, Isoprenaline, Catecholamine, Vitamin, Partnership, Norepinephrine, Carbidopa/levodopa, Adrenaline, L-DOPA, Phenelzine, Mouth, Hearing, Physician, Neoplasm, Dyskinesia, Medication, Somnolence, Accident, Dizziness, Tranylcypromine, Weight loss, Psychosis, Pharmaceutical industry, Birth control, S.A, Amneal Pharmaceuticals, LD

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and BIAL - Portela & Ca., S.A. (“BIAL”), today announced a licensing agreement where Amneal will have exclusive rights to market and distribute ONGENTYS® (opicapone) in the U.S. starting on December 18, 2023.
  • Carbidopa/levodopa (CD/LD), which works to control the symptoms of PD, has been the gold-standard treatment for PD since the 1970s.
  • ONGENTYS® works by inhibiting the COMT enzyme – which breaks down LD – making more LD available to reach the brain, thereby reducing “Off” time.
  • The financial terms of the agreement were not disclosed, and any incremental expenses associated with this product are contemplated within Amneal’s guidance.

Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”

Retrieved on: 
星期三, 八月 2, 2023
Pharmaceutical, Health, Neurology, COPD, Glaucoma, Mental toughness, Hallucination, Asthma, Psychosis, ACOR, Butyrophenone, Medicine, Education, Wheeze, Friends, Phenothiazine, Somnolence, Fever, Phenelzine, PWP Heavyweight Championship, Dopamine, Açorda, Risperidone, Fighter, Capsule, L-DOPA, Dizziness, Tranylcypromine, Patient, Gambling, Nausea, Confusion, Perspiration, Dyskinesia, Acorda Therapeutics, OFF, Metoclopramide, Upper respiratory tract infection, Therapy, Sleep, Bronchospasm, Family, Saliva, Disease, Pharmaceutical industry, Birth control, Interior design

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched a new INBRIJA (levodopa inhalation powder) website and brand campaign.
  • INBRIJA is not to be used by people who have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine, within the last 2 weeks.
  • I’m determined to make every day, every moment, count, and to live a full life with my family and friends.
  • The most common side effects of INBRIJA are cough, upper respiratory tract infection, nausea, and change in the color of saliva or spit.

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

Retrieved on: 
星期一, 十二月 5, 2022
Professional Services, Health, Neurology, Other Health, Finance, Pharmaceutical, Travel, ACOR, Therapy, Security (finance), Inhalation, 4-Aminopyridine, Judgement, Note, Intellectual property, Patient, Açorda, Research, Tablet, Consultant, COVID-19, Acorda Therapeutics, Tranylcypromine, Senior, OFF, Phenelzine, Failure, Workforce, Patent, Risk, Pharmaceutical industry

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture.
  • Acorda may elect to make interest payments under the Indenture in cash or shares of the Companys common stock.
  • The Company made the interest payment using cash that was placed in escrow when the Notes were issued, which is reported on the Companys balance sheet as restricted cash.
  • By making this interest payment in cash, the Company has ensured that there was no dilution to shareholders.

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Retrieved on: 
星期五, 十一月 11, 2022
Neurology, Health, Science, Pharmaceutical, Research, CEO, U.S. Securities and Exchange Commission, Judgement, Tablet, Workforce, 4-Aminopyridine, Company, Failure, Reverse stock split, Patent, Travel, Acorda Therapeutics, Therapy, Phenelzine, Tranylcypromine, Security (finance), Consultant, Technology, Research, Risk, Patient, OFF, Goal, Forward-looking statement, COVID-19, ACOR, Nasdaq, Intellectual property, Inhalation, Pharmaceutical industry

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.
  • We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one.
  • Authorizing our board to implement a reverse stock split is an important tool, if needed, to ensure that we do not become delisted by Nasdaq, said Ron Cohen, M.D., President and CEO of Acorda Therapeutics.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Retrieved on: 
星期五, 十一月 4, 2022
Neurology, Health, Science, Pharmaceutical, Research, Online, Proxy, Company, Research, Special, Workforce, Patent, Nasdaq, OFF, Investor, Intellectual property, Judgement, 3rd Floor, Supplement, Acorda Therapeutics, COVID-19, Therapy, Tranylcypromine, Review, Reverse stock split, Phenelzine, Inhalation, Proxy statement, Failure, U.S. Securities and Exchange Commission, Travel, Forward-looking statement, Risk, Spring of Two Blue J's, 4-Aminopyridine, Goal, Technology, Security (finance), SEC, Tablet, Patient, ACOR, Consultant, Holding company, Mail, Auction

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR ) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split.
  • The sole matter of business before the reconvened Special Meeting will be to approve Proposal Two, the Reverse Stock Split.
  • Proposal Three, allowing the Special Meeting to be adjourned, was approved at the Special Meeting.
  • The record date for determining stockholders eligible to vote on Proposal Two at the reconvened Special Meeting remains September 9, 2022.

Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance

Retrieved on: 
星期四, 十月 27, 2022
Neurology, Health, Science, Pharmaceutical, Research, Online, Nasdaq, U.S. Securities and Exchange Commission, Review, Symphony, Goal, Investor, Travel, Phenelzine, Reverse stock split, Forward-looking statement, COVID-19, Technology, Tranylcypromine, Therapy, Patient, 4-Aminopyridine, Workforce, Company, Proxy statement, Inhalation, OFF, Judgement, Research, Lists of diseases, Special, Policy, SEC, Tablet, Risk, Intellectual property, Supplement, BlueJeans, Patent, Proxy, Consultant, Failure, Security (finance), Online gambling, Mail, Pharmaceutical industry, Auction, Açorda

Acorda will hold a video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET / 10:00am PT.

Key Points: 
  • Acorda will hold a video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET / 10:00am PT.
  • The call will review Acordas long-term business plan and the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022.
  • Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Retrieved on: 
星期二, 十月 25, 2022
Neurology, Health, Science, Pharmaceutical, Research, U.S. Securities and Exchange Commission, Risk, Therapy, Investor relations, Investor, Tablet, Tranylcypromine, Acorda Therapeutics, NASDAQ, Patient, Inhalation, Research, Security (finance), Workforce, Judgement, Lists of diseases, Technology, Goal, Nasdaq, 4-Aminopyridine, Phenelzine, Q&A, Patent, Intellectual property, Forward-looking statement, Travel, Failure, COVID-19, OFF, Consultant, ACOR, Pharmaceutical industry, Webcast

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m.
  • After you have registered, you will receive a confirmation email with the Webcast details.
  • On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join.
  • The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com .

Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.

Retrieved on: 
星期五, 十月 21, 2022
Pharmaceutical, Health, Neurology, Online, U.S. Securities and Exchange Commission, Risk, Therapy, PT, Tablet, Tranylcypromine, Acorda Therapeutics, Patient, Inhalation, Research, Security (finance), Workforce, Judgement, Lists of diseases, Nasdaq, Technology, Goal, 4-Aminopyridine, BlueJeans, Phenelzine, Patent, Reverse stock split, Intellectual property, Forward-looking statement, Travel, Failure, COVID-19, OFF, Consultant, Online gambling, Mail, Pharmaceutical industry

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT.
  • The call will review the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022.
  • To participate in the video event:
    Click the link below from a laptop or mobile device.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Retrieved on: 
星期三, 十月 19, 2022
General Health, Health, Other Health, Online, U.S. Securities and Exchange Commission, Risk, Therapy, Tablet, Tranylcypromine, Acorda Therapeutics, ISS, LLC, Patient, Inhalation, Research, Security (finance), Workforce, Judgement, Lists of diseases, Technology, Elias Neocleous & Co LLC, Goal, 4-Aminopyridine, Phenelzine, Patent, Reverse stock split, Intellectual property, Forward-looking statement, Travel, Failure, COVID-19, OFF, Consultant, ACOR, Holding company, Mail, Pharmaceutical industry, Nasdaq, Shareholder

We appreciate the confirmation of the need for and urgency of this proposal, said John P. Kelley, Chair of Acordas Board of Directors.

Key Points: 
  • We appreciate the confirmation of the need for and urgency of this proposal, said John P. Kelley, Chair of Acordas Board of Directors.
  • The proposal to allow the board to implement a reverse split, if necessary, is critical to ensure that Acorda does not become delisted from Nasdaq.
  • If delisting were to occur, we may be in default on our agreements with our debtholders, and may need to declare bankruptcy.
  • Stockholders are encouraged to cast your vote promptly FOR the Reverse Split proposal without further delay.

Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt

Retrieved on: 
星期二, 十月 18, 2022
General Health, Health, Other Health, U.S. Securities and Exchange Commission, Risk, Therapy, Tablet, Tranylcypromine, Acorda Therapeutics, Patient, Inhalation, Research, Security (finance), Workforce, Judgement, Lists of diseases, Nasdaq, Senior, Technology, Açorda, Goal, 4-Aminopyridine, Phenelzine, Patent, Intellectual property, Forward-looking statement, Travel, Failure, COVID-19, OFF, Consultant, ACOR, Pharmaceutical industry

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will not use its common stock to make the approximately $6.2 million interest payment due on December 1, 2022, as provided for under its Convertible Senior Secured Notes Indenture.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will not use its common stock to make the approximately $6.2 million interest payment due on December 1, 2022, as provided for under its Convertible Senior Secured Notes Indenture.
  • Under the terms of the agreement with bondholders, Acorda may elect to pay interest in cash or shares of the Companys common stock.
  • Not paying in shares of common stock will ensure that there will be no dilution to shareholders.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.